US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
January 03, 2024 09:46 ET
|
Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not...
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
January 03, 2024 07:33 ET
|
Arch Biopartners
TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the...
U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement
December 13, 2023 14:03 ET
|
Spherix Global Insights
Exton, PA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS)....
ShapeTX Expands Strategic Collaboration with Roche with Addition of a New Target
November 30, 2023 08:00 ET
|
Shape Therapeutics, Inc.
ShapeTX announces the expansion of its drug discovery partnership with Roche with new target
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023 07:00 ET
|
Synlogic, Inc.
- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 - - Progress of the Synpheny-3 pivotal trial...
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
November 07, 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema
November 01, 2023 14:55 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has...
Synlogic to Participate in Chardan’s Genetic Medicines Conference
September 21, 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis
July 27, 2023 16:00 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists with...
Jnana Therapeutics Announces Milestone Achieved Under First Collaboration with Roche
May 24, 2023 07:00 ET
|
Jnana Therapeutics, Inc.
Achievement of research milestone for immune program triggers milestone payment BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its...